Pathogenesis and management of Kawasaki disease

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 2, 2010, Pages 197-203

  Rowley, Anne H ^a   Shulman, Stanford T ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

coronary artery aneurysms; cytoplasmic inclusion bodies; IgA immune response; IgA plasma cells; inclusion bodies; intravenous immunoglobulin; Kawasaki disease; synthetic antibodies; vasculitis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; WARFARIN;

CELL INCLUSION; CELL INFILTRATION; CORONARY ARTERY ANEURYSM; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ECHOCARDIOGRAPHY; ENZYME RELEASE; FEVER; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOGENESIS; INFLAMMATORY CELL; LONG TERM CARE; LOW DRUG DOSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; INFANT; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; RISK ASSESSMENT;

CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MUCOCUTANEOUS LYMPH NODE SYNDROME; RISK ASSESSMENT;

EID: 77954468538     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.09.109     Document Type: Review

References (49)

1. Amano S, Hazama F, Kubagawa H, Tasaka K, Haebara H, Hamashima Y. General pathology of Kawasaki disease. On the morphological alterations corresponding to the clinical manifestations. Acta Pathol. Jpn 30(5), 681-694 (1980). Comprehensive autopsy study of 37 Japanese children with fatal kawasaki disease (KD), detailing the high incidence of inflammatory lesions in many organs and tissues.
2. Rowley AH, Baker SC, Orenstein JM, Shulman ST. Searching for the cause of Kawasaki disease -cytoplasmic inclusion bodies provide new insight. Nat. Rev. Microbiol. 6(5), 394-401 (2008). Review of etiologic, pathologic and immunologic studies in KD, including the discovery that viral-like cytoplasmic inclusion bodies are present in KD tissues, and proposing a model of KD pathogenesis based upon available data.
3. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J. Infect. Dis. 184(7), 940-943 (2001).
4. Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J. Immunol. 159(12), 5946-5955 (1997).
5. Rowley AH, Shulman ST, Mask CA et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J. Infect. Dis. 182(4), 1183-1191 (2000).
6. Yilmaz A, Rowley A, Schulte DJ et al. Activated myeloid dendritic cells accumulate and co-localize with CD3+ T cells in coronary artery lesions in patients with Kawasaki disease. Exp. Mol. Pathol. 83(1), 93-103 (2007).
7. Hirao J, Hibi S, Andoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int. Arch. Allergy Immunol. 112(2), 152-156 (1997). (Pubitemid 27039179)
8. Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor a among patients with Kawasaki disease. J. Pediatr. 121(6), 924-926 (1992).
9. Maury CP, Salo E, Pelkonen P. Elevated circulating tumor necrosis factor-a in patients with Kawasaki disease. J. Lab. Clin. Med. 113(5), 651-654 (1989).
10. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler. Thromb. Vasc. Biol. 23(4), 576-581 (2003).
11. Yasukawa K, Terai M, Shulman ST et al. Systemic production of vascular endothelial growth factor and FMS-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 105(6), 766-769 (2002).
12. Freeman AF, Crawford SE, Cornwall ML, Garcia FL, Shulman ST, Rowley AH. Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium. Pediatr. Cardiol. 26(5), 578-584 (2005).
13. Miura M, Garcia FL, Crawford SE, Rowley AH. Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease. Pediatr. Infect. Dis. J. 23(10), 931-936 (2004).
14. Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J. Immunol. 166(2), 1334-1343 (2001).
15. Rowley AH, Baker SC, Shulman ST et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J. Infect. Dis. 190(4), 856-865 (2004).
16. Rowley AH, Shulman ST, Garcia FL et al. Cloning the arterial IgA antibody response during acute Kawasaki disease. J. Immunol. 175(12), 8386-8391 (2005).
17. Rowley AH, Baker SC, Shulman ST et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J. Infect. Dis. 192(10), 1757-1766 (2005). Light and electron microscopic study of cytoplasmic inclusion bodies detected by KD synthetic antibody, showing that they are consistent with aggregates of viral proteins and nucleic acids.
18. Rowley AH, Baker SC, Shulman ST et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS ONE 3(2), e1582 (2008). Study demonstrating the presence of RNA-containing cytoplasmic inclusion bodies in 85% of acute and late-stage KD fatalities, and in 25% of adult controls, consistent with the hypothesis that KD is the result of infection with a previously unidentified, ubiquitous, persistent RNA virus.
19. Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 112(3 Pt 1), 495-501 (2003).
20. Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: Results from the nationwide survey in 2005-2006. J. Epidemiol. 18(4), 167-172 (2008).
21. Onouchi Y. Molecular genetics of Kawasaki disease. Pediatr. Res. 65(5 Pt 2), 46R-54R (2009). Summary of genetic studies of KD, including a description of newer, more powerful genetic methods to identify the multiple genes probably involved in predisposition to KD.
22. Onouchi Y, Tamari M, Takahashi A et al. A genomewide linkage analysis of Kawasaki disease: Evidence for linkage to chromosome 12. J. Hum. Genet. 52(2), 179-190 (2007).
23. Onouchi Y, Gunji T, Burns JC et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet. 40(1), 35-42 (2008).
24. Burgner D, Davila S, Breunis WB et al. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet. 5(1), e1000319 (2009).
25. Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of g globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324(23), 1633-1639 (1991).
26. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous g globulin. N. Engl. J. Med. 315(6), 341-347 (1986). Classic multicenter treatment trial that showed a single large (2 g/kg) dose of intravenous immunoglobulin (IVIG) to be superior to four once-daily infusions in acute KD, with lower rates of development of coronary abnormalities and prompter normalization of inflammatory markers.
27. Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J. Pediatr. 140(4), 450-455 (2002).
28. Muta H, Ishii M, Egami K et al. Early intravenous g-globulin treatment for Kawasaki disease: The nationwide surveys in Japan. J. Pediatr. 144(4), 496-499 (2004).
29. Zhang T, Yanagawa H, Oki I, Nakamura Y. Factors relating to the cardiac sequelae of Kawasaki disease one month after initial onset. Acta Paediatr. 91(5), 517-520 (2002).
30. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on g globulin dose but independent of salicylate dose. J. Pediatr. 131(6), 888-893 (1997).
31. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 114(6), 1708-1733 (2004). Comprehensive statement from the appropriate committee of the American Heart Association that details diagnosis, treatment and long-term management principles. (Pubitemid 41754943)
32. Jibiki T, Terai M, Kurosaki T et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J. Pediatr. 163(4-5), 229-233 (2004).
33. Inoue Y, Okada Y, Shinohara M et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: Clinical course and coronary artery outcome. J. Pediatr. 149(3), 336-341 (2006).
34. Newburger JW, Sleeper LA, McCrindle BW et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med. 356(7), 663-675 (2007). This very well done clinical trial did not show a clear benefit of adding a single dose of intravenous methylpredisone to therapy with 2 g/kg IVIG and high-dose aspirin for acute KD.
35. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr. Infect. Dis. J. 23(5), 463-464 (2004).
36. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. g globulin re-treatment in Kawasaki disease. J. Pediatr. 123(4), 657-659 (1993).
37. Burns JC, Mason WH, Hauger SB et al. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr. 146(5), 662-667 (2005).
38. Burns JC, Best BM, Mejias A et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr. 153(6), 833-838 (2008).
39. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous g-globulin treatment failure in Kawasaki disease. Pediatrics 105(6), E78 (2000).
40. McMorrow Tuohy AM, Tani LY, Cetta F et al. How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease? Am. J. Cardiol. 88(3), 328-330 (2001).
41. Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics 100(4), 695-699 (1997).
42. Gotteiner N, Mavroudis C, Backer CL et al. Coronary artery bypass grafting for Kawasaki disease. Pediatr. Cardiol. 23(1), 62-67 (2002).
43. Ishii M, Ueno T, Akagi T et al. Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr. Int. 43(5), 558-562 (2001).
44. Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 109(1), E4 (2002).
45. Sugimura T, Yokoi H, Sato N et al. Interventional treatment for children with severe coronary artery stenosis with calcification after long-term Kawasaki disease. Circulation 96(11), 3928-3933 (1997).
46. Kitamura S, Tsuda E, Kobayashi J et al. Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. Circulation 120(1), 60-68 (2009). This unique Japanese study reports long- term (median follow up: 19 years) outcomes for 114 children and adolescents who underwent coronary bypass surgery for KD complications. The 25-year survival rate was 95%, cardiac event-free rates at 20 and 25 years were 67% and 60%, respectively, and over all 20-year graft potency rate was 87% for internal thoracic artery and 44% for saphenous vein grafts.
47. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2(8154), 1216-1217 (1979).
48. Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 2(8397), 255-256 (1984).
49. Kenyon RH, Condie RM, Jahrling PB, Peters CJ. Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: Importance of elimination of infected cells. Microb. Pathog. 9(4), 219-226 (1990).